Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Janssen (J&J Innovative Medicine)

Status

Conditions: Adenomatous Polyposis Coli

Treatments: Drug: Guselkumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04948398

CR108964

CNTO1959APC4001 (Other Identifier)

Details and patient eligibility

About

The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria